Abstract
We examined the relation between ERBB2 gene expression (as determined by a real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal patients with breast cancer. Although ERBB2 overexpression was associated with shorter relapse-free survival in univariate analysis (P = 0.00029), ERBB2 did not persist as an independent prognostic factor in multivariate analysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous variable, the higher the ERBB2RNA level, the poorer the outcome (P = 0.00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
Translated title of the contribution | ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma |
---|---|
Original language | English |
Pages (from-to) | 173 - 178 |
Journal | Cancer Letters |
Volume | 174 (2) |
Publication status | Published - Dec 2001 |
Bibliographical note
Publisher: Elsevier Sci Ireland LtdOther identifier: IDS Number: 494AH